Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-bridge Cycle01:26

Cross-bridge Cycle

121.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
121.8K
Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
6.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subjective memory complaints in adults with epilepsy reflect affective and attentional processes rather than objective memory performance.

Epilepsy & behavior : E&B·2026
Same author

Three case reports of optic perineuritis complicated by ocular scleritis and hypertrophic pachymeningitis.

Journal of neuroimmunology·2026
Same author

A Novel Dysferlin-Binding Kinase CK2α Promotes Plasma Membrane Repair in Dysferlinopathy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Gadolinium enhancement of the cauda equina in a case of familial ALS with p.S135G <i>SOD1</i> mutation.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Response to the Letter by Dr. Zarrouk et al.

Internal medicine (Tokyo, Japan)·2026
Same author

Addendum to the 2023 clinical practice guidelines for amyotrophic lateral sclerosis in Japan: approval and integration of novel disease-modifying therapies.

Rinsho shinkeigaku = Clinical neurology·2026

Related Experiment Video

Updated: Jan 3, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K

[Familial Amyotrophic Lateral Sclerosis].

Naoki Suzuki1, Ayumi Nishiyama, Masaaki Kato

  • 1Department of Neurology, Tohoku University Hospital.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|November 14, 2019
PubMed
Summary

Familial amyotrophic lateral sclerosis (ALS) involves genetic mutations, with SOD1 common in Japan and C9orf72 in the West. This review details clinical features, mechanisms, and emerging therapies for familial ALS.

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K

Related Experiment Videos

Last Updated: Jan 3, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease.
  • Current treatments in Japan include riluzole and edaravone.
  • Familial ALS accounts for about 10% of cases and is linked to specific gene mutations.

Purpose of the Study:

  • To review the clinical characteristics of familial ALS based on causative mutations.
  • To discuss the pathomechanisms of ALS, including proteostasis, RNA metabolism, and axonal pathology.
  • To examine the development of therapeutic strategies for familial ALS.

Main Methods:

  • Literature review of genotype-phenotype correlations in familial ALS.
  • Detailed discussion of ALS pathomechanisms.
  • Analysis of animal models and induced pluripotent stem cells for therapeutic development.

Main Results:

  • SOD1 mutations are frequent in Japanese familial ALS, while C9orf72 mutations are more common in Western countries.
  • Genotype-phenotype correlations aid in establishing disease models.
  • Various pathomechanisms contribute to motor neuron degeneration in ALS.

Conclusions:

  • Understanding genotype-phenotype relationships is crucial for familial ALS research.
  • Targeting proteostasis, RNA metabolism, and axonal pathology offers therapeutic avenues.
  • Preclinical studies in animal models and iPSCs show promise for future familial ALS treatments.